Skip to content
    CNC
    Earnings call· Dec 2025(Q4 FY25)

    CENTENE Q4 FY25 earnings call CNC

    Feb 6, 2026 Source

    Executive summary

    Centene Q4 FY25 — Strong Q4 Performance and Positive 2026 Outlook with Expected EPS Growth

    Centene navigated a challenging 2025, closing the year ahead of expectations with improved Medicaid profitability and favorable Marketplace medical cost trends in Q4. The company is positioned for meaningful margin improvement and renewed adjusted EPS growth in 2026, driven by Medicaid stabilization, Marketplace recovery, and continued progress in Medicare Advantage, despite ongoing policy-related variability and No Surprises Act challenges.

    Highlights

    5
    • Full year 2025 adjusted diluted EPS of $2.08, slightly ahead of expectations.

    • Medicaid profitability improved, with Q4 HBR at 93.0%, representing 40 basis points of sequential improvement and 190 basis points from Q2 levels.

    • Underlying medical cost trend within Marketplace and Medicare segments was in line to slightly favorable in Q4.

    • Marketplace risk adjustment showed favorable development for 2025, resulting in a couple hundred million of net P&L outperformance in Q4.

    • PDP business delivered strong 2025 performance despite Inflation Reduction Act headwinds.

    Concerns

    4
    • Fourth quarter adjusted diluted loss per share of $1.19.

    • Marketplace segment HBR was roughly 100 basis points higher than original expectations due to a 2023 CMS reconciliation and increased accruals related to the No Surprises Act.

    • Medicare Advantage HBR was slightly elevated in Q4 due to a review of provider contract portfolio and adjustments.

    • The 2027 advanced notice suggests a more pressured view of Medicare rates than industry expectations.

    Guidance & targets

    16
    CategoryTargetConfidence
    Full year 2026 adjusted diluted EPS
    greater than $3
    high materiality
    High
    Medicaid HBR
    stable
    medium materiality
    Medium
    Medicaid net rate impact
    mid-4s
    medium materiality
    Medium
    Medicaid net trend expectation
    mid-4s
    medium materiality
    Medium
    Medicaid member months reduction
    5% to 6%
    medium materiality
    Medium
    Marketplace membership
    roughly 3.5 million members
    high materiality
    High
    Marketplace pretax margin
    around 4%
    high materiality
    Medium
    Medicare Advantage breakeven goal
    breakeven
    high materiality
    Medium
    Part D enrollment growth
    high single-digit percentage growth
    medium materiality
    High
    Medicare segment premium revenue growth
    approximately $7.5 billion
    medium materiality
    Medium
    Consolidated HBR
    90.9% to 91.7%
    high materiality
    High
    PDP pretax margin
    around 2%
    medium materiality
    Medium
    Adjusted tax rate
    26% to 27%
    low materiality
    Medium
    Premium and service revenue
    $170 million to $174 billion
    high materiality
    High
    Debt-to-cap ratio
    continued pay down
    medium materiality
    Medium
    Seasonality of 2026 adjusted EPS
    majority in Q1, stepping down in Q2, around breakeven in Q3, loss in Q4
    low materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    Medicaid
    Medicaid profitability improved in the back half of 2025, with Q4 HBR consistent with expectations. Underlying medical cost trend patterns remained largely consistent with Q3, with behavioral health, home health, and high-cost drugs driving excess trends. 1/1 final rates were in line with expectations.
    HBR Q4: 93.0%Sequential HBR improvement: 40 bpsHBR improvement from Q2: 190 bpsMembership (end of 2025): 12.5 million
    Commercial (Marketplace)
    Underlying medical cost trend was slightly better than expectations in Q4. The Q4 HBR was higher due to a 2023 CMS reconciliation and accruals for No Surprises Act disputes. Ambetter membership developed in line with expectations for Q1 2026, with a notable shift to Bronze plans.
    Q4 HBR: ~1 point higher than forecastQ1 2026 ending membership (expected): ~3.5 millionBronze membership (2026): >30% of enrollment
    Medicare
    Fundamental Medicare Advantage performance in Q4 was in line with expectations. PDP business delivered strong performance in 2025. MA membership is expected to decline intentionally in Q1 2026 as part of a strategy to refine footprint and value proposition. Part D enrollment is tracking well for Q1 2026.
    PDP enrollment growth (Q1 2026 vs YE 2025): high single-digit percentageMedicare Advantage revenue (2026): essentially flatMedicare segment revenue mix (2026): 41% MA / 59% PDP

    Operational metrics

    14
    Adjusted diluted EPS
    -$1.19
    Q4 FY25

    Fourth quarter adjusted diluted loss per share.

    Adjusted diluted EPS
    $2.08
    FY25

    Full year adjusted diluted EPS.

    GAAP diluted loss per share
    -$2.24
    Q4 FY25

    Includes a $389 million net loss from the divestiture of the remaining Magellan business.

    SG&A expense ratio
    7.5%
    Q4 FY25

    Q4 adjusted SG&A expense ratio.

    SG&A expense ratio
    7.4%110 bps lower than 2024
    FY25

    Full year adjusted SG&A expense ratio, reflecting continued discipline and scale.

    Cash available for general corporate use
    $400 million
    End of FY25

    Balance at the end of the year.

    Debt reduction
    $189 million
    Q4 FY25

    Amount of debt reduced in the fourth quarter.

    Medical claims liability
    $20.5 billion
    End of FY25

    Total medical claims liability.

    Days in claims payable (DIP)
    46 daysdecrease of 2 days QoQ
    End of FY25

    Decrease driven by payouts of state-directed payments and elimination of Medicare premium deficiency reserve.

    Direct subsidy (PDP)
    $200up from $143
    2026

    Reflecting industry pricing for higher pharmacy trends due to the IRA.

    Marketplace pricing increase
    mid-30%
    2026

    Pricing actions taken to adequately capture market shifts, trends, and policy changes.

    Medicaid composite rate adjustment
    approximately 5.5%above 2024 levels
    2025

    Composite rate adjustment for 2025, matured favorably from initial expectations.

    Marketplace revenue reduction
    ~$8 billion
    2026

    Driven by policy and market impacts, including expiration of enhanced APTCs, net of rate increases.

    Medicare PDP pretax margin
    well into the 3s
    2025

    Pretax margin for the PDP business in 2025.

    Industry KPIs

    10
    MetricValueDetails
    Utilization trends
    Stars rate environment
    Medical loss care ratio90.9% to 91.7%%
    Pharmacy scripts specialty
    Membership covered lives by line12.5 millionmembers
    Segment revenue operating income$170 billion to $174 billionUSD
    Prior year reserve development pdreliminated
    Adjusted EPS EBITDA leverage guidancegreater than $3USD
    Prior authorization operational metrics
    Medical cost trend vs pricing assumptionmid-4s%

    Deals & partnerships

    1
    Not specifieddivestiture$389 million net loss

    A definitive agreement to divest the remaining Magellan business was reached in Q4 2025, resulting in a net loss. Centene had previously divested Magellan pharmacy and specialty businesses at gains over the past few years.

    Risks & headwinds

    3
    No Surprises Act (NSA) disputes and fraudulent manipulationOngoing

    Accruals for 2025 dates of service pushed Marketplace HBR up roughly 100 bps. A multimillion-dollar lawsuit was filed against a New York provider.

    Mitigation: Taking a more proactive litigious posture, advocating for NSA reform, and aggressive action to protect the system from fraudulent exploitation of loopholes.

    Policy-related variability and landscape volatility2026 and beyond

    Not explicitly quantified, but incorporated into the prudent 2026 outlook.

    Mitigation: Prudently positioned 2026 outlook, focus on execution, and identifying continued opportunities for margin expansion.

    Pressured Medicare rates from 2027 advanced notice2027

    Suggests a more pressured view of rates than industry expectations.

    Mitigation: Will provide CMS comments on the advanced notice and construct 2027 bids with the goal of achieving breakeven performance in Medicare Advantage.

    Q&A highlights

    8

    Why is the 2026 Medicaid rate expectation of 4.5% not higher given elevated trends, and is it conservative? Can mid-year rate increases be expected?

    The 4.5% rate assumption for 2026 is prudent, noting that 2025 rates matured favorably to 5.5%. The current rate cycle benefits from two full years of acuity and trend data, informing rate decisions. States are also making program changes, such as addressing ABA outlier providers and PBM control, which act as proxies for rate adjustments and contribute to trend bending.

    we're starting with a prudent assumption around that 4.5% for 2026. I would point to the fact that our 2025 rates matured favorably from where we started at the beginning of 2025 and ended with that composite rate at roughly 5.5%.

    asked by Ann Hynes · answered by Sarah London

    2 min read6 chapters

    Detailed Narrative

    01

    Medicaid Profitability and Trend Management

    Centene demonstrated significant progress in restoring Medicaid profitability in the back half of 2025, with the Q4 HBR improving to 93.0%, a 40 basis point sequential improvement and 190 basis points from Q2 levels. Key drivers of excess trend, including behavioral health, home health, and high-cost drugs, remained consistent. The company is actively managing costs through network optimization, clinical programs, rate advocacy, and aggressive fraud detection, exemplified by the ABA task force which identified and addressed outlier providers and inappropriate care patterns.

    02

    Marketplace Repositioning and Risk Adjustment

    The Marketplace business saw fundamental medical cost trends slightly better than expected in Q4, and a favorable change in the view of 2025 risk adjustment. Despite the expiration of enhanced advanced premium tax credits, Ambetter membership is on track for approximately 3.5 million members by the end of Q1 2026, with over 30% enrolled in Bronze plans. Centene anticipates a meaningful payable position for 2026 risk adjustment and is working with Wakely to publish a report for industry visibility on market dynamics.

    03

    Medicare Strategy and IRA Impact

    Centene's Medicare segment delivered strong results in 2025, with Q4 performance in line with expectations. The company is progressing towards its goal of breakeven Medicare Advantage results in 2027, intentionally reducing MA membership while increasing yields. The PDP business performed strongly in 2025 despite Inflation Reduction Act headwinds, and 2026 enrollment is tracking to high single-digit percentage growth. The 2027 advanced notice suggests pressured rates, but Centene remains focused on profitability and quality.

    04

    No Surprises Act (NSA) Challenges and Litigation

    The No Surprises Act has become a source of increased costs and disputes, leading to a roughly 100 basis point increase in the Marketplace HBR in Q4 due to accruals for 2025 service dates. Centene views the NSA as being 'weaponized' by market participants and is advocating for reform. The company is adopting a more proactive and litigious posture, including filing a multimillion-dollar lawsuit against a New York provider for alleged fraudulent manipulation of claims.

    05

    Technology and AI Integration for Efficiency

    Centene is systematically integrating AI into its operations to drive efficiency and enhance member experience. This includes proof points in accelerated prior authorization approvals, improved call center operations, enhanced member navigation, and advanced analytics for medical economics and payment integrity. The company plans to accelerate the integration of Generative AI and agentic capabilities into core operations in 2026 to drive automation and reimagine stakeholder experiences.

    06

    Capital Allocation and Debt Management

    Centene ended 2025 with approximately $400 million of cash available for general corporate use. The company reduced debt by $189 million in Q4, bringing the debt-to-cap ratio to 46.5%. While no share buyback is reflected in the 2026 guidance, Centene will continue to assess capital deployment opportunities as it generates excess cash and aims for continued deleveraging to reduce interest expense.

    AI-generated summary of the company’s earnings call. Not investment advice.